相关实验视频

Updated: Jan 13, 2026

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

临床参数和生物标志物的意义,以预测宁泰达尼布诱导的腹:基于采访的回顾性研究

Toru Arai¹, Masakazu Hiramatsu^2,3, Naoko Takeuchi⁴

¹Clinical Research Center, NHO Kinki Chuo Chest Medical Center, Sakai City, Osaka, Japan.

Journal of thoracic disease

|January 12, 2026

概括

在间歇性肺部疾病 (ILD) 患者中,丁丁达尼布诱导的腹与异常性肺纤维化 (IPF),不使用皮质类固醇,较高的药物剂量和较低的肺功能等因素有关. 像单细胞计数和表面活性蛋白D这样的生物标志物也可能预测这种副作用.

科学领域:

肺部病理学肺部病理学
药理学药理学是指药理学的学科.
生物标志物生物标志物

背景情况:

异形性肺纤维化 (IPF) 和渐进性肺纤维化 (PPF) 是严重的纤维化肺病.
丁丁达尼布是一种治疗方法,可以减缓肺功能下降,并改善IPF和其他具有PPF的ILD的生存率.
腹是宁泰达尼布常见且显著的副作用,往往导致停止治疗.

研究的目的:

在患有间歇性肺部疾病 (ILDs) 的患者中确定宁泰达尼布诱导的腹的临床预测因素.
评估ILD生物标志物在预测宁泰达尼布诱导腹中的作用.
在评估生物标志物的重要性时,调整显著的临床预测因素.

主要方法:

七十九个ILD患者接受了任泰达尼布治疗,被追溯分析.
通过采访和医疗记录来评估腹的发生.
测量了包括血清表面活性蛋白-D (SP-D) 和外周血液单细胞计数在内的生物标志物.
使用后勤回归分析来确定预测能力.

主要成果:

在47名患者中,在3个月内发生了因丁达尼布诱导的腹.
多变量分析显示IPF,没有皮质类固醇治疗,每人体表面积 (BSA) 较高的宁泰达尼布剂量,以及较低的%强迫生命能力 (%FVC) 预测了早期腹.
在调整其他因素后,较低的单细胞计数 (≤650/μL) 和较高的血清SP-D (>157.5 ng/mL) 与腹有关.

结论:

丁丁达尼布诱导的腹是多因素的,受临床特征和生物标志物的影响.
IPF,缺乏皮质类固醇使用,较高的宁泰达尼布剂量和肺功能降低是关键的临床预测因素.
低单细胞计数和血清SP-D升高可能表明患上宁泰达尼布诱导腹的风险较高,需要进一步调查.

关键词:

在M2巨细胞中.尼丁达尼比是什么意思腹腹腹腹腹腹一个单细胞单细胞.表面活性蛋白-D (SP-D) 是一种表面活性蛋白.

更多相关视频

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

相关概念视频

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...